Stereotactic Ablative Radiotherapy for Early-stage Glottic Larynx Cancer

Not Applicable

Completed

• Conditions: Glottic Carcinoma
• Interventions: Radiation: Radiation therapy

• Registration Number: NCT03548285
• Lead Sponsor: University of Texas Southwestern Medical Center

Brief Summary

This is a prospective study to determine the local control and quality-of-life outcomes of using SBRT for early-stage glottic larynx cancer.

Detailed Description

SBRT treatment will be delivered to patients diagnosed with stage I-II glottic larynx cancer twice per week for 5 fractions (42.5 Gy cohort, low-risk) or daily for 16 fractions (58.08 Gy cohort, moderate-risk).

Low-risk is defined by:

* Planning target volume (PTV) less than 10 cc, AND

* No reported smoking within 1 month from registration

Moderate-risk is defined by:

* Planning target volume (PTV) greater than or equal to 10 cc, OR

* Smoking within 1 month from registration (no more than 1 pack per day)

Study Timeline

• Study First Submitted: 2018-05-03
• Study Start: 2018-05-15
• Study First Submitted QC: 2018-06-06
• Study First Posted: 2018-06-07
• Primary Completion: 2023-04-25
• Study Completion: 2024-04-30
• Results First Submitted: 2024-09-23
• Results First Submitted QC: 2025-04-07
• Results First Posted: 2025-04-25
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-07
• Last Update Posted: 2025-05-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

1. Pathologically-proven diagnosis of squamous cell carcinoma in situ, squamous cell carcinoma or squamous cell variants (sarcomatoid, verrucous, basaloid, and papillary subtypes) involving the glottic larynx.

2. Clinical stage I-II (American Joint Committee on Cancer AJCC, 7th edition) with direct laryngoscopy showing no evidence of greater than stage II true glottic larynx cancer and PET/CT or CT neck showing no evidence of regional disease.

3. Age ≥ 18 years.

4. ECOG Performance Status 0-2

5. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

   5.1 A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

   • Has not undergone a hysterectomy or bilateral oophorectomy; or
   • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

6. Negative serum or urine pregnancy test within 2 weeks before registration for women of childbearing potential.

7. Ability to understand and the willingness to sign a written informed consent.

8. Patients with cognitive impairment or other limited decision making capacity with the ability to understand and willingly sign written informed consent or have the consent signed by a designated legally authorized representative (LAR)

Exclusion Criteria

1. AJCC stage III or stage IV larynx cancer
2. Involvement of the arytenoid cartilage beyond the vocal process.
3. Prior chemotherapy for treatment of the targeted larynx lesion
4. Synchronous primaries in the head and neck
5. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation fields.
6. Subjects smoking in excess of 1 pack of cigarettes per day.
7. Subjects may not be receiving any other investigational agents.
8. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
9. Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
patient with low risk	Radiation therapy	Low-risk is defined by: * Planning target volume (PTV) less than 10 cc, AND * No reported smoking within 1 month from registration Radiation Therapy will be delivered twice per week for 5 fractions (total 42.5 Gy)
patient with moderate risk	Radiation therapy	Moderate-risk is defined by: * Planning target volume (PTV) greater than or equal to 10 cc, OR * Smoking within 1 month from registration (no more than 1 pack per day) Radiation Therapy will be delivered daily for 16 fraction (total 58.08 Gy)

Primary Outcome Measures

Name	Time	Method
Number of Patients With Local Failure Following SABR Treatment of Early Glottic Larynx Cancers	2 years	Local failure is defined as biopsy-proven tumor anywhere on the true vocal cords.

Secondary Outcome Measures

Name	Time	Method
Percentage of Patient Population With Regional Failure and Distant Metastasis	2 years	With death and prior locoregional failure as competing risks
Laryngectomy-free Survival	2 years	Laryngectomy-free survival probability at 2 years
Voice-quality Score Following Treatment With SABR	From baseline to 2 years post-treatment	Voice Handicap Index (VHI) voice-quality score to monitor changes in self-perception of voice handicap before and after treatment.; 0-30 Mild Minimal amount of handicap 31-60 Moderate handicap 60-120 Severe handicap
Number of Patients With Grade 3-5 Acute and Late Toxicities Following Treatment With SABR	90 days, 3 years	Number of patients with grade 3-5 acute (start of treatment through 90 days from the completion of treatment) and late (after 90 days from the completion of treatment) adverse events, according to NCI's Common Terminology Criteria for Adverse Events (CTCAE) v4.0 toxicity criteria.
Health-related Quality of Life Following Treatment With SABR.	From baseline to 2 years post-treatment	Average patient visual analogue scale score (derived from EQ-5D) at baseline, 6, 12, and 24 months from the end of treatment; The Visual Analogue Score (VAS) of the EQ-5D is a visual scale from 0-100, with 100 being perfect health, where patients can mark their perceived health. Researchers can then take the average score across all patients for each timepoint.
Percentage of Participants With Locoregional Failure Following SABR With Death as a Competing Risk	2 years	Specifically, the 2-year cumulative risk of biopsy-proven recurrence anywhere in the larynx or neck following SABR. Recurrence in this context includes biopsy-proven cancer anywhere in the supraglottic, glottic, or subglottic larynx, as well as any malignant lymph node in the cervical or supraclavicular lymph nodes.
Overall Survival	2 years	Overall survival

Trial Locations

Locations (1)

University of Texas Southwestern Medical Center; 🇺🇸 Dallas, Texas, United States